Avsnitt
-
In this investigative episode, Mike explores the complex reasons behind America’s poor health outcomes despite leading the world in healthcare spending. From ultra-processed foods and insulin resistance to chronic inflammation and the promise of new weight-loss drugs, we unravel the biology, environment, and policy factors driving obesity and chronic disease in the U.S. A must-listen for healthcare professionals seeking a deep dive into the nation’s health crisis.
-
In this investigative episode, Mike dives deep into the unprecedented decision by Health Secretary Robert F. Kennedy Jr. to abruptly fire the entire CDC Advisory Committee on Immunization Practices (ACIP). Exploring the implications for public health, trust in vaccines, and healthcare policy, we examine the controversial backgrounds of new appointees and the urgent reactions from the medical community. What does this political shakeup mean for vaccination rates, patient care, and the future of science-based healthcare in America?
-
Saknas det avsnitt?
-
We survey healthcare professionals constantly—on treatments, on tech, on trends. But how often is that research actually used to shape decisions? And what do clinicians really think about being surveyed in the first place?
In this episode, we unpack the role of HCP market research in today’s healthcare economy. Why it’s done, how it’s evolving, and whether it still holds real value. Featuring insights from industry insiders and critical reflections on how pharma and MedTech listen—or don’t—to the voices of frontline care.
-
In this episode of Curie, we dive into the early but extraordinary results from two CAR-T cell therapy trials that are rewriting what’s possible for glioblastoma—a brain cancer with a devastating prognosis. Andrew takes you through new data from Mass General and the University of Pennsylvania, where some patients have not just responded, but are alive and well nearly two years after treatment.
With quotes from top researchers like Dr. Bryan Choi and Dr. Stephen Bagley, we explore how this groundbreaking treatment works, why a few patients are experiencing durable remissions, and what hurdles remain before CAR-T can become a viable option for more people with this lethal disease.
Is glioblastoma finally meeting its match? Tune in to find out.
-
In this extended wrap-up from ASCO 2025, Mike breaks down four defining themes from the meeting: AI’s leap from buzzword to bedside, NIH funding threats that could shake innovation, China’s rising role in global oncology R&D, and five paradigm-shifting clinical trials with the potential to reshape patient care. Featuring insights from ASCO leadership, Google, and frontline HCPs from the ZoomRx panel, this is your all-in-one debrief on the most important takeaways from the year’s biggest oncology conference.
-
Trump’s drug pricing executive order might sound bold—but what’s behind the rhetoric? In this episode of Curie, host Andrew sits down with Dr. David Introcaso, healthcare policy expert and host of The Healthcare Policy Podcast, to unpack the legal, economic, and political minefield that surrounds America’s $5 trillion healthcare system.
From Medicare price negotiations to pharma's pushback, Dr. Introcaso offers a sharp, no-nonsense take on what’s at stake, what’s realistic, and why this moment might signal a deeper reckoning with how the U.S. approaches cost, coverage, and care.
This is a must-listen conversation for any healthcare professional trying to make sense of drug pricing headlines—and what they mean for clinical practice.
-
In 2024, over twenty-seven thousand fewer Americans died of a drug overdose—a reversal so steep it stunned even veteran public health researchers. This episode unpacks the factors behind the historic decline: from naloxone’s expanded access to the work of drug-testing labs like UNC’s Opioid Data Lab. We also hear from voices on the front lines, including NPR’s Brian Mann and UNC’s Dr. Nabarun Dasgupta, who remind us that while the tide may be turning, the work is far from over.
Visit curie.md for more curated podcasts, medical news, and games built for healthcare professionals.
-
GLP-1s like Ozempic and Zepbound transformed obesity and diabetes treatment. But when shortages hit, compounding pharmacies and telehealth startups filled the gap with off-brand versions—cheap, accessible, and often unregulated.
Now, that workaround is over.
In this episode, we examine the FDA’s sweeping May 2025 ban on compounded GLP-1 drugs. What triggered it? What are the safety risks? And why is the industry suddenly pivoting to an older, less effective drug: liraglutide?
With interviews, data, and regulatory context, we break down:
Why Olympia Pharmaceuticals stopped producing semaglutideWhy liraglutide is gaining traction despite its limitationsWhat the FDA has reported about dosing errors, hospitalizations, and even deathsHow insurance gaps and policy shifts continue to limit accessWhat healthcare professionals should consider when restarting patients or navigating new formulariesThis isn’t just a regulatory update—it’s a turning point in the story of obesity treatment in America.
-
Artificial intelligence is transforming how we detect disease—but what does that mean for the clinician-patient relationship? In this conversation, Dr. Andrew Wilner and Andrew Yukawa explore how diagnostic AI is reshaping everything from radiology to primary care. Together, they unpack the promise, the pitfalls, and the deeply human elements that machines still can’t replicate. From clinical judgment to patient trust, we ask: Where does AI stop, and where must the physician begin?
-
In 2025, a six-month-old with a fatal genetic disorder became the first person to receive a CRISPR-based therapy tailored to their unique mutation. In this episode of Curie, host Mike unpacks how a team of researchers and clinicians raced against time to design, test, and deliver a one-time treatment that rewrote the rules of genomic medicine. From the science of base editing to the ethical and logistical hurdles, this is the story of what it took to make personalized gene therapy a reality—and what it means for the future of rare disease care.
-
A sweeping new executive order from Donald Trump promises to slash prescription drug prices by up to 80%. But behind the bold rhetoric lies a tangle of legal uncertainty, international trade implications, and real clinical consequences. In this episode of Curie, host Mike breaks down what’s actually in the order, why the pharmaceutical industry is pushing back, and what it all means for healthcare professionals. Will your patients benefit—or will this gamble on affordability come at the cost of access?
-
Ob/Gyns are walking away—and it's not just burnout. In this episode of Curie, we investigate the legal, financial, and political forces driving the crisis in women’s health. What happens when an entire specialty starts to disappear?
-
From ADHD to borderline personality disorder, mental health content is exploding on TikTok—and teens are listening. But is this wave of awareness helping patients, or muddying the waters for clinicians? In this episode of Curie, we explore how social media is changing the way symptoms are understood, identities are formed, and diagnoses are pursued. Featuring insights from clinicians and research on the rising intersection between mental health and the algorithm.
-
In this post-conference episode, Mike breaks down five major stories from AACR 2025:
KEYNOTE-689 trial changes the standard of care in head and neck cancerZongertinib delivers HER2-targeted efficacy with fewer side effects in lung cancerCAR NK cells show durable remission in AMLctDNA testing in CRC detects recurrence 6+ months before imagingWerner helicase inhibitor shows first-in-class potential in MSI tumorsListen in for a concise roundup of the data and why it matters.
-
Once considered a short-term fix or semi-retirement gig, locum tenens has become a deliberate career choice for tens of thousands of physicians across the U.S.
We discuss:
What people still misunderstand about locum tenensHow variety and exposure shape clinical growthWhy more doctors are walking away from traditional career tracksThe traits that make someone a great fit for locums—and the traits that don’tWhether we’re entering a new chapter in what it means to have a “successful” medical careerWhether you’re considering locum work yourself, or just curious about where physician careers are headed, this is a conversation worth hearing.
-
A plan to link together massive datasets about autistic Americans has triggered fierce debate. Critics fear it’s a surveillance effort in disguise. Federal agencies say it’s about research. And the autistic community? They're raising serious concerns about privacy, ethics, and unintended consequences. In today’s episode of Curie, Mike unpacks what’s happening inside the Department of Health and Human Services under Secretary Robert F. Kennedy Jr., what’s true, what’s not, and what it could mean for the future of neurodivergent Americans. Love what you hear? Download the Curie app for personalized, in-depth healthcare podcasts curated just for you.
-
Seventy years ago, Jonas Salk changed history with the first successful polio vaccine—an innovation that reshaped public health and saved millions of lives. But what does his legacy mean in a world now grappling with vaccine skepticism, science politicization, and resurging preventable diseases? In this episode of Curie, we reflect on Salk’s radical generosity, the ethics of scientific discovery, and what today’s healthcare professionals can still learn from his example.
-
In this Curie episode, Matt previews what’s coming at AACR 2025, happening April 25–30 in Chicago. Get ready for a data-packed week with practice-changing trials like KEYNOTE-689 and Beamion LUNG-1, along with fresh momentum in AI-powered oncology, cancer interception, and new modalities like peptide drug conjugates and RNA-targeting agents. From early detection to trial equity, this preview outlines the trends and themes every oncologist should be watching ahead of the meeting.
-
A cancer vaccine? It’s not science fiction anymore. In this episode of Curie, host Andrew unpacks a groundbreaking personalized vaccine trial led by Dr. Vinod Balachandran at Memorial Sloan Kettering. By training the immune system to recognize mutations unique to each patient’s tumor, this approach is rewriting the rules of cancer care. We explore how mRNA, long known for its role in COVID vaccines, could become the blueprint for a new era in oncology—one that’s personal, programmable, and potentially transformative.
-
In this special Curie episode, Matt covers the biggest clinical updates from the 2025 American Academy of Neurology Annual Meeting. Learn how CNM-Au8 is showing real signs of remyelination in MS, why AXS-05 may be the next approved treatment for Alzheimer’s agitation, and how Vyepti is delivering long-term migraine relief. We also spotlight Mi-Helper, a noninvasive cooling device for migraines, and the Felix NeuroAI wearable, a smart wristband reducing essential tremor through AI-guided stimulation. Tune in for expert quotes, clinical relevance, and cutting-edge neurology updates.
- Visa fler
